Anti-PGP9.5 antibody (ab106656)
- Product nameAnti-PGP9.5 antibodySee all PGP9.5 primary antibodies ...
- DescriptionRabbit polyclonal to PGP9.5
- Tested applicationsIHC-FoFr, WB more details
- Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Horse, Cow, Dog, Pig, Xenopus laevis, Cynomolgus Monkey
Synthetic peptide, corresponding to amino acids 187-202 of Human PGP9.5(P09936)
- Positive control
- IHC-Fo-Fr: Dorsal root ganglion WB: Solubilized Human brain extract; Mouse hippocampal lysates
- Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
- Storage bufferPreservative: 0.05% Sodium Azide
Constituents: Whole serum
- PurityWhole antiserum
- Clonality Polyclonal
- Research Areas
Our Abpromise guarantee covers the use of ab106656 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|IHC-FoFr||IHC-FoFr: 1/500 - 1/1000.|
|WB||WB: 1/1000 - 1/2000. Predicted molecular weight: 25 kDa.|
- FunctionUbiquitin-protein hydrolase involved both in the processing of ubiquitin precursors and of ubiquitinated proteins. This enzyme is a thiol protease that recognizes and hydrolyzes a peptide bond at the C-terminal glycine of ubiquitin. Also binds to free monoubiquitin and may prevent its degradation in lysosomes. The homodimer may have ATP-independent ubiquitin ligase activity.
- Tissue specificityFound in neuronal cell bodies and processes throughout the neocortex (at protein level). Expressed in neurons and cells of the diffuse neuroendocrine system and their tumors. Weakly expressed in ovary. Down-regulated in brains from Parkinson disease and Alzheimer disease patients.
- Involvement in diseaseDefects in UCHL1 are the cause of Parkinson disease type 5 (PARK5) [MIM:613643]; also known as Parkinson disease autosomal dominant 5. PARK5 is a complex neurodegenerative disorder with manifestations ranging from typical Parkinson disease to dementia with Lewy bodies. Clinical features include parkinsonian symptoms (resting tremor, rigidity, postural instability and bradykinesia), dementia, diffuse Lewy body pathology, autonomic dysfunction, hallucinations and paranoia.
- Sequence similaritiesBelongs to the peptidase C12 family.
- Cellular localizationCytoplasm. Endoplasmic reticulum membrane. About 30% of total UCHL1 is associated with membranes in brain.
- Entrez Gene: 514394 Cow
- Entrez Gene: 479098 Dog
- Entrez Gene: 100033838 Horse
- Entrez Gene: 7345 Human
- Entrez Gene: 22223 Mouse
- Entrez Gene: 396637 Pig
- Entrez Gene: 29545 Rat
- Omim: 191342 Human
- SwissProt: P23356 Cow
- SwissProt: Q60HC8 Cynomolgus Monkey
- SwissProt: Q9GM50 Horse
- SwissProt: P09936 Human
- SwissProt: Q9R0P9 Mouse
- SwissProt: Q6SEG5 Pig
- SwissProt: Q00981 Rat
- Unigene: 518731 Human
- Unigene: 29807 Mouse
- Unigene: 107213 Rat
- Neuron cytoplasmic protein 9.5 antibody
- OTTHUMP00000218137 antibody
- OTTHUMP00000218139 antibody
- OTTHUMP00000218140 antibody
- OTTHUMP00000218141 antibody
- Park 5 antibody
- PARK5 antibody
- PGP 9.5 antibody
- PGP9.5 antibody
- PGP95 antibody
- Protein gene product 9.5 antibody
- Ubiquitin C terminal esterase L1 antibody
- Ubiquitin C terminal hydrolase antibody
- Ubiquitin carboxyl terminal esterase L1 antibody
- Ubiquitin carboxyl terminal hydrolase isozyme L1 antibody
- Ubiquitin carboxyl-terminal hydrolase isozyme L1 antibody
- Ubiquitin thioesterase L1 antibody
- Ubiquitin thiolesterase antibody
- Ubiquitin thiolesterase L1 antibody
- UCH-L1 antibody
- UCHL1 antibody
- UCHL1_HUMAN antibody
Anti-PGP9.5 antibody images
ab106656, at a 1/500 dilution, staining PGP9.5 in dorsal root ganglion by Immunohistochemistry.
Antiserum was used on perfusion fixed tissue. Perfusion: 1) calcium-free Tyrode’s solution, 2) fixative, and 3) 10% sucrose in PBS as a cryo-protectant. Desired tissues were dissected and stored overnight in 10% sucrose in PBS. Slide-mounted tissue sections were processed for indirect immunofluorescence. Slides were incubated with blocking buffer for 1 hour at room temperature. Primary antiserum was diluted with blocking buffer to the appropriate working concentration. Blocking buffer was removed and slides were incubated for 18-24 hours at 4ºC with primary antiserum. Slides were rinsed 3 times and then incubated with secondary antibodies for 1 hour at room temperature. Slides were again rinsed 3 times and coverslipped. Staining was examined using fluorescence microscopy.
References for Anti-PGP9.5 antibody (ab106656)
ab106656 has not yet been referenced specifically in any publications.